Lexeo CEO sells 55K shares under 10b5-1 plan

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan reported an open-market sale of 55,000 shares of common stock at a weighted average price of $5.6934 per share.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan reported an open-market sale of 55,000 shares of common stock at a weighted average price of $5.6934 per share. The sale on April 6, 2026 was made under a pre-arranged Rule 10b5-1 trading plan.

Following this transaction, Nolan directly holds 340,106 shares of Lexeo common stock, which includes 261,349 Restricted Stock Units that may convert into shares if vesting conditions are satisfied.

Insider Trade Summary 10b5-1

Net Seller: 55,000 shares

Net Sell 1 txn

Insider Townsend Richard Nolan

Role Chief Executive Officer

Sold 55,000 shs ($313K)

Type	Security	Shares	Price	Value
Sale	Common Stock	55,000	$5.6934	$313K

Holdings After Transaction: Common Stock — 340,106 shares (Direct)

Footnotes (3)

1. F1. The sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $5.56 to $5.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Includes 261,349 Restricted Stock Units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Key Figures

Shares sold: 55,000 shares Weighted average sale price: $5.6934 per share Post-transaction holdings: 340,106 shares +3 more

6 metrics

Shares sold 55,000 shares Open-market sale on April 6, 2026

Weighted average sale price $5.6934 per share Common stock sale on April 6, 2026

Post-transaction holdings 340,106 shares Directly held by CEO after transaction

Restricted Stock Units 261,349 RSUs Included in CEO’s reported holdings

Price range of trades $5.56 to $5.94 Multiple executions within the reported sale

Trading plan adoption date November 13, 2025 Rule 10b5-1 plan governing the sale

Key Terms

Rule 10b5-1 trading plan, Restricted Stock Units (RSU's), weighted average sale price, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Restricted Stock Units (RSU's) financial

"Includes 261,349 Restricted Stock Units (RSU's). Each RSU represents a contingent right..."

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lexeo Therapeutics (LXEO) report for its CEO?

Lexeo Therapeutics reported that CEO Richard Nolan sold 55,000 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $5.6934 per share on April 6, 2026, according to a Form 4 filing.

Was the Lexeo (LXEO) CEO stock sale made under a trading plan?

Yes. The CEO’s sales were made under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions, as described in the Form 4 footnotes.

What price range did the Lexeo (LXEO) CEO receive for the sold shares?

The transaction was executed in multiple trades at prices ranging from $5.56 to $5.94 per share. The Form 4 reports a weighted average sale price of $5.6934 per share across the 55,000 shares sold in this transaction.

How many Lexeo (LXEO) shares does the CEO hold after the reported sale?

After the sale, CEO Richard Nolan directly holds 340,106 shares of Lexeo common stock. This total includes 261,349 Restricted Stock Units, each representing a contingent right to receive one share if applicable vesting conditions are met.

What are the Restricted Stock Units (RSUs) held by the Lexeo (LXEO) CEO?

The CEO’s reported holdings include 261,349 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Lexeo common stock, subject to the specific vesting schedules and other conditions attached to each RSU grant.

Is the Lexeo (LXEO) CEO’s transaction an open-market sale or another type?

The filing identifies the transaction as an open-market sale of common stock, coded as “S” on Form 4. This indicates a sale in the market or a private transaction, distinct from option exercises, grants, gifts, or tax-withholding events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/06/2026		S(1)		55,000	D	$5.6934(2)	340,106(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. This transaction was executed in multiple trades at prices ranging from $5.56 to $5.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 261,349 Restricted Stock Units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Youjin Choi, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)